








Amendments to the Claims:

1. (original) A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H₃ receptor antagonist / m₂ muscarinic antagonist.
2. (original) The method of claim 1 wherein the dual H₃/m₂ antagonist is selected from the group consisting of





and



Claims 3 to 13 (withdrawn)

14. (currently amended) A method of treating cognition deficit disorders comprising administering to a mammal in need of such treatment an effective amount of a dual histamine H₃ antagonist/m₂ muscarinic antagonist or an effective amount of a combination of a histamine H₃ receptor antagonist and a m₂ muscarinic antagonist, in combination with an effective amount of an acetylcholinesterase inhibitor.

15. (currently amended) A pharmaceutical composition comprising an effective amount of a dual histamine H₃ antagonist/ m₂ muscarinic antagonist
~~or a combination of a histamine H₃ antagonist and a m₂ muscarinic antagonist,~~ in further combination with an acetylcholinesterase inhibitor and a pharmaceutically acceptable carrier.

16. (withdrawn)